Compare PSQH & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | INKT |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.4M | 51.7M |
| IPO Year | N/A | 2021 |
| Metric | PSQH | INKT |
|---|---|---|
| Price | $1.09 | $11.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 596.7K | 20.6K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,534,522.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.08 | N/A |
| 52 Week Low | $0.92 | $4.56 |
| 52 Week High | $5.18 | $76.00 |
| Indicator | PSQH | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 50.06 |
| Support Level | $1.07 | $11.33 |
| Resistance Level | $1.22 | $12.31 |
| Average True Range (ATR) | 0.10 | 0.73 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 31.58 | 46.54 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.